BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join
back to Directory

Recursion Pharmaceuticals

Recursion Pharmaceuticals logo

Website
https://www.recursion.com/
Founded
2013
Patents
16
Clinical Trials
4
Publications
25

Technologies

AI Companies (Drug Discovery) Gene Therapy Startups Pharmaceutical and Drug Discovery

Recursion Pharmaceuticals is a biotechnology company based in Salt Lake City. Recursion combines experimental biology, automation, and artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, and immunology. Recursion is aggressively leveraging technology to build a robust and reliable map of human cellular biology, which will enable a radical shift in the pace and scale at which new treatments will benefit patients.


Posts Mentioning This Company

19 Companies Pioneering AI Foundation Models in Pharma and Biotech

June 19, 2024  
Foundation models represent a new paradigm in artificial intelligence (AI), revolutionizing how machine learning models are developed and deployed. As these models grow increasingly capable, they become useful for applications across a wide range of economic functions and industries, including biotech. Foundation models are a class of large-scale machine learning …
13 Publicly Traded AI-driven Drug Discovery Companies

13 Publicly Traded Biotechs Utilizing AI-based Research Platforms (+ 2 Upcoming Public Debuts)

June 18, 2024  
According to our intelligence report, The State of Artificial Intelligence (AI) in the Biopharma Industry, more than 450 life sciences companies in the categories "startups" and "scaleups" are actively using machine learning and deep learning-based predictive and generative capabilities to augment their research strategies.  Some companies are incorporating AI tools …

The Growing Momentum for AI Foundation Models in Biotech and 12 Notable Companies

March 17, 2024  
As artificial intelligence (AI) foundation models grow increasingly capable, they become useful for applications across a wide range of economic functions and industries, including biotech. The most prominent examples of general purpose foundation models are the GPT-3 and GPT-4 models, which form the basis of ChatGPT, and BERT, or Bidirectional …
Top AI Drug Discovery Companies Transforming the Pharma Industry

Tech-First Companies Take the Lead in AI Drug Discovery

Nov. 27, 2023  
In recent news, Recursion (NASDAQ: RXRX), a prominent clinical stage TechBio firm, has announced the signing of agreements to acquire Cyclica and Valence, two companies with expertise in AI-enabled drug discovery. These acquisitions strengthen Recursion's position in computational chemistry, machine learning, and artificial intelligence, enhancing its technology-enabled drug discovery capabilities …
6 Ways Big Pharma Leverages AI To Boost Drug Discovery

How Big Pharma Adopts AI To Boost Drug Discovery

July 6, 2023  
(Last updated: July 2023) The type of artificial intelligence (AI) which scares business leaders, experts, and activists all over the world, is called “general artificial intelligence"—the  one which could “think” pretty much like humans do, and which could quickly evolve into a dangerous “superintelligence”. There is a notion that it …

A Parade of AI-driven Biotechs Going Public in 2020-2021

Sept. 24, 2021  
Over 2020-2021 we have seen a remarkable parade of artificial intelligence (AI), focused on discovering novel therapeutics, going public. This reflects a continuing interest in AI as a transformative technology for the pharmaceutical industry and increasing belief in the wave of technology-driven “neo-biotechs”. Here we list some notable companies which …

Pharmaceutical AI in 2021: Key Developments So Far

Aug. 9, 2021  
Table of Contents:   Introduction Artificial intelligence (AI) in drug discovery yields breakthroughs The abundance of venture capital, major funding rounds IPOs of AI Pharma Companies in 2021 New AI-driven biotech startups founded in 2020 Notable AI-focused collaborations involving “big pharma” players AI adoption by the contract research organizations (CROs)  …
Artificial Intelligence Yields Early Results in Drug Discovery

Artificial Intelligence Yields Early Results in Drug Discovery

April 7, 2019  
A historically significant milestone has just been reached by Oxford, UK-based Exscientia, which used its artificial intelligence (AI)-based drug discovery platform Centaur Chemist™ to deliver the first drug candidate in the framework of their multiyear collaboration with GSK. This AI-derived small molecule is a highly potent in vivo active substance …
Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

Sept. 12, 2018  
Today Basel is crowded with some of the top business and research leaders representing a young and rapidly growing industry of artificial intelligence (AI) in healthcare and pharmaceutical research. They come together to announce mission and launch activities of a global Alliance for Artificial Intelligence in Healthcare (AAIH), which is …
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

R&D Platform

Conduct experimental biology at scale by testing thousands of compounds on hundreds of cellular disease models in parallel. Allows researchers to: Rapidly identify new indications for many known drugs and shelved assets.

News

  • 2025-06-07
    MIT and Recursion Launch Boltz-2, Open-Source AI Foundation Model for Structure and Binding Affinity Prediction
  • 2024-12-09
    Recursion Reports Encouraging Interim Phase 1 Data a Selective CDK7 Inhibitor
  • 2024-08-08
    Breaking: In Arguably the Largest AI in Bio Deal, Recursion Acquires UK-based "End-to-End" AI Biotech Exscientia
  • 2024-05-14
    Recursion Unveils BioHive-2, Fastest Pharma-Owned Supercomputer
  • 2024-04-03
    New Landmark Report Unveils a Decade of AI Transformation in Drug Discovery
  • 2024-03-11
    Recursion Expands Its Presence with a New London Office and Bolsters Scientific Advisory Team
  • 2022-06-06
    Insilico Medicine Snaps Up $60M to Create Robotic Lab of the Future

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.